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What is already known 
mTOR is a serine/threonine kinase and 
downstream member of the PI3K/protein 
kinase B (AKT) and adenosine monophos-
phate-activated protein kinase pathways, 
with an essential role in cell growth, sur-
vival and autophagy. mTOR is a compo-
nent of two structurally similar complexes, 
mTORC1 and mTORC2, which are, 
however, functionally distinct. mTORC1 
promotes mRNA translation and protein 
synthesis by phosphorylation of ribosomal 
protein S6 kinase and eIF4E-binding pro-
tein 1 and inhibits autophagy. mTORC2 
organizes the cellular actin cytoskeleton and 
regulates AKT phosphorylation, promoting 
cell survival. AKT requires phosphorylation 
by both PI3K and mTORC2 in order to be 
fully activated. In low cellular energy levels, 
liver kinase B1 tumor suppressor activates 
the adenosine monophosphate-activated 
protein kinase pathway, which negatively 
regulates the mTOR pathway through the 
tuberin (TSC1)/hamartin (TSC2) com-
plex. Furthermore, PTEN is an additional 
negative regulator of mTOR [1–5].
The PI3K/mTOR pathway is often 
found dysregulated in cancer, promoting 
cancer survival and growth. Mutations 
can occur in any component of the PI3K 
pathway, resulting in its dysregulation. 
In breast cancer, PIK3CA mutations 
have been commonly identified, occur-
ring at a frequency of 27–36% [6]. The 
luminal A subtype of breast cancer had 
the highest frequency of PIK3CA muta-
tion (45%) and the basal subtype had the 
lowest (9%). Additional identified aber-
rations resulting in the dysregulation of 
the PI3K/mTOR pathway include Akt 
and PTEN mutations, or loss of PTEN 
expression [7,8].
The concept of mTOR inhibition in 
breast cancer was firstly supported by pre-
clinical evidence demonstrating activation 
of the PI3K/mTOR pathway after long-
term estrogen deprivation [9,10]; estrogen-
deprived cells rely heavily on the PI3K 
signaling pathway, making this an impor-
tant mechanism of acquired endocrine 
resistance. Combined use of antiestrogens 
(tamoxifen/letrozole) with rapamycin ana-
logs demonstrated increased antitumor 
activity and reversal of endocrine resist-
ance secondary to PI3K/mTOR activation 
in p reclinical models [11,12].
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many potentially exciting 
implications that can 
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In the metastatic setting, clinical trials using 
single-agent mTOR inhibitors demonstrated 
modest activity with a response rate ranging 
between 9 and 12% [13]. In an effort to enrich 
for PIK3CA mutations, a clinical trial of tem-
sirolimus alone in hormone receptor-positive 
or HER2-positive metastatic breast cancer 
patients, failed to demonstrate higher activity. 
PIK3CA mutations were not associated with 
a higher response rate, however the primary 
tumors were associated with it that were ana-
lyzed, and not the recurrent or metastatic sites 
that may have obscured a true association [14]. 
A large Phase III trial, randomizing postmeno-
pausal patients with metastatic hormone recep-
tor-positive breast cancer between temsirolimus 
and letrozole or letrozole alone had to be closed 
prematurely due to lack of efficacy, disappointing 
the scientific community at the time. However, 
as the trial limited the use of mTOR inhibition 
in the first-line metastatic setting, the negative 
results were attributed to the lack of previous 
exposure to estrogen deprivation which would 
upregulate the PI3K/mTOR pathway and drive 
tumors to become dependent on it for their 
survival and growth [15]. The TAMRAD study 
randomized patients with prior exposure to an 
aromatase inhibitor (AI) in the metastatic set-
ting, to tamoxifen alone versus combination of 
tamoxifen and everolimus. [16] The combined 
treatment was associated with higher clinical 
benefit rate (42 vs 61%; p = 0.045) and time 
to progression (4.5 vs 8.6 months; hazard ratio 
[HR]: 0.54; 95% CI: 0.36–0.81; p = 0.002). 
When patients were stratified based on primary 
hormone resistance, defined as relapse dur-
ing adjuvant AI therapy or progression within 
6 months of AI treatment in the metastatic 
setting versus secondary hormone resistance, 
defined as late relapse or progression on an AI 
in the metastatic setting more than 6 months 
after treatment, it was obvious that patients with 
secondary endocrine resistance were associated 
with a higher clinical benefit ratio and time to 
progression when compared with patients with 
primary hormonal resistance, further supporting 
the theory that upfront estrogen deprivation is 
required to prime tumors to be dependent on 
the PI3K/mTOR pathway. The above results 
were further supported by the BOLERO-2 study 
randomizing patients with advanced hormone 
receptor-positive breast cancer, whose disease had 
progressed on a nonsteroidal AI, to combination 
examestane and everolimus or examestane alone, 
and demonstrated superior progression-free sur-
vival with the combination (4.1 vs 10.6 months; 
HR: 0.36; 95% CI: 0.27–0.47; p < 0.001) [17].
There is also substantial preclinical evidence 
that the PI3K/mTOR pathway is also impli-
cated in the development of resistance in HER2-
amplified disease. In a cohort of 55 breast cancer 
patients, activation of the PI3K pathway, assessed 
by the presence of oncogenic PIK3CA mutations 
or low PTEN expression, was associated with 
poor prognosis after trastuzumab therapy, and 
the combined analysis of PTEN and PIK3CA 
identified twice as many patients at increased risk 
for progression compared with PTEN alone [18]. 
Similarly in HER2 overexpressing cell lines, the 
combination of trastuzumab and the Akt inhibitor 
triciribine inhibited breast cancer cell growth and 
induced apoptosis, with similar results observed 
from xenograft models. The combination of tras-
tuzumab and the mTOR inhibitor RAD001 also 
impeded breast cancer cell growth in vitro and 
in vivo [19]. In another study using various breast 
cancer cell lines innately resistant to trastuzumab 
or lapatinib, it was demonstrated that loss of PTEN 
or the presence of activating mutations in PI3K 
were associated with resistance to trastuzumab, 
which could be reversed by l apatinib through the 
dephosphorylation of AKT [20].
Encouraging results were obtained from a 
clinical study of everolimus in combination 
with paclitaxel and trastuzumab in trastuzumab-
refractory HER2-positive metastatic breast can-
cer, which demonstrated clinical activity with an 
overall response rate of 44% and control of dis-
ease for 6 months or more in 74% of the patients 
[21]. Similarly, a Phase I study combining everoli-
mus with weekly trastuzumab and vinorelbine 
in pretreated HER2-positive metastatic breast 
cancer revealed an overall response rate of 19.1%, 
control rate of 83% and median progression-free 
survival of 7 months, approximately [22]. Using 
the dual PI3K/mTOR inhibitor, BEZ235, in 
combination with trastuzumab in patients with 
metastatic HER2-positive breast cancer bearing 
mutations in PIK3CA/PTEN or loss of PTEN 
by immunohistochemistry, a Phase I/Ib clinical 
study demonstrated a clinical benefit rate of 27%. 
Interestingly, no associations of responses with 
PI3K pathway alterations were identified [23].
Despite the infrequency of PIK3CA muta-
tions in triple-negative breast cancer, gene profil-
ing analysis in this disease identified six distinct 
molecular subtypes, amongst which mesenchy-
mal and mesenchymal stem cell-like subtypes, 
“...carefully designed 
large-scale clinical trials are 
needed to demonstrate 
the groups of patients 
benefiting the most from 
the inhibition of the 
PI3K/mTOR pathway...”
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which were sensitive to dual PI3K/mTOR inhibi-
tors [24]. Subsequently, a small Phase II trial with 
everolimus and carboplatin in patients with met-
astatic triple-negative breast cancer identified a 
clinical benefit rate of 38% [25].
What is the way forward?
It is becoming clear that carefully designed large-
scale clinical trials are needed to demonstrate the 
groups of patients benefiting the most from the 
inhibition of the PI3K/mTOR pathway; this is 
substantiated by the evidence supporting that prior 
estrogen deprivation is required to prime tumors to 
become dependent on the PI3K/mTOR pathway 
as they gradually evolve toward the development 
of endocrine resistance. Given the recent evidence 
supporting the extension of adjuvant endocrine 
treatment for up to 10 years in patients with high-
risk hormone receptor-positive breast cancer and 
the lack of evidence of PI3K/mTOR inhibition 
in the adjuvant setting currently, it would be very 
interesting to quantify the potenttial benefit of 
the addition of everolimus to standard endocrine 
treatments in the adjuvant setting, after 2–3 years 
of initial antiestrogens alone (ClinicalTrials 
i dentifier: NCT01805271) [26].
Immunohistochemical analysis or even gene 
profiling looking for aberrations of the pathway 
components in the primary tumor is not adequate 
to select appropriate patients with a high prob-
ability to respond to trialed treatments, as the 
results from previous clinical trials analyzing 
primary tumors are rather contradictive. Repeat 
biopsies are becoming essential and should be 
encouraged within clinical trials to identify and 
investigate biomarkers of resistance and treat-
ment efficacy at the molecular level through deep 
sequencing techniques. We anticipate with great 
interest the results of clinical trials investigating 
the efficacy of dual PI3K/mTOR inhibitors, as 
the effects of the first generation mTOR inhibi-
tors have thus far been rather modest, most likely 
due to ‘molecular escape routes’ of cancer cells via 
the activation of alternative survival pathways. 
Simultaneous inhibition of more than one path-
way, in other words, PI3K/mTOR and IGFR is a 
concept that should be considered, as supported 
by a growing amount of preclinical evidence. 
The reversal of resistance to EGFR treatments 
would be of paramount significance for patients 
with HER2-positive breast cancer who have pro-
gressed on previous trastuzumab, and therefore 
the final results of the BOLERO-1/3 trials as 
well as other studies investigating the efficacy 
of the addition of mTOR inhibitors to ongoing 
chemotherapy and trastuzumab are also greatly 
anticipated.
The field of PI3K/mTOR inhibition in breast 
cancer remains highly active with many poten-
tially exciting implications that can revolutionize 
the clinical management of patients. Relevant 
preclinical research and support of the ongoing 
clinical trials should be strongly recommended.
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